Genetic Technologies Ltd (NASDAQ:GENE) — Stock Price
Genetic Technologies Ltd (NASDAQ:GENE) is currently trading at $2013.75 USD, down 0.57% today. Over the past 52 weeks, shares have ranged between $1843.60 and $2043.75. This page tracks Genetic Technologies Ltd's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Genetic Technologies Ltd market cap and net worth.
Genetic Technologies Ltd (GENE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Genetic Technologies Ltd's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Genetic Technologies Ltd Income Statement — Revenue, Profit & Earnings by Year
Genetic Technologies Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $7.66 Million | $10.35 Million | $6.79 Million | $120.55K | $9.86K |
| Cost of Revenue | $3.76 Million | $4.34 Million | $321.22K | $361.03K | $251.51K |
| Gross Profit | $3.90 Million | $6.01 Million | $6.47 Million | $-240.47K | $-241.65K |
| Research & Development | $752.75K | $1.28 Million | $705.51K | $3.11 Million | $2.48 Million |
| SG&A | $10.22 Million | $1.36 Million | $2.18 Million | $4.16 Million | $4.06 Million |
| Total Operating Expenses | $16.11 Million | $18.11 Million | $3.11 Million | $7.00 Million | $6.03 Million |
| Operating Income | $-12.21 Million | $-10.42 Million | $-7.54 Million | $-7.06 Million | $-6.08 Million |
| EBITDA | $-11.43 Million | $-11.20 Million | $-7.20 Million | $-7.06 Million | $-6.08 Million |
| EBIT | $-11.97 Million | $-11.88 Million | $-7.78 Million | $-7.06 Million | $-6.08 Million |
| Interest Expense | $51.62K | $29.52K | $15.21K | $14.05K | $14.82K |
| Income Before Tax | $-12.02 Million | $-11.91 Million | $-7.16 Million | $-7.08 Million | $-6.10 Million |
| Income Tax Expense | $-1.99 Million | $-158.33K | $-32.12K | $130.32K | $205.15K |
| Net Income | $-12.02 Million | $-11.75 Million | $-7.13 Million | $-7.21 Million | $-6.30 Million |
Genetic Technologies Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Genetic Technologies Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $6.19 Million | $14.86 Million | $20.80 Million | $22.97 Million | $15.63 Million |
| Total Current Assets | $3.70 Million | $10.50 Million | $14.72 Million | $22.24 Million | $15.19 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $18.79K | $17.44K | $13.26K | $1.86K | $2.02K |
| Net Receivables | $2.13 Million | $191.90K | $2.42 Million | $1.07 Million | $38.87K |
| Inventory | $206.47K | $325.89K | $398.15K | $76.93K | $91.39K |
| Property, Plant & Equipment | — | $599.18K | $953.33K | $637.71K | $440.23K |
| Goodwill | $1.78 Million | $3.12 Million | $4.51 Million | $4.51 Million | — |
| Total Liabilities | $4.36 Million | $3.69 Million | $4.37 Million | $1.44 Million | $1.64 Million |
| Total Current Liabilities | $4.20 Million | $3.31 Million | $3.81 Million | $1.41 Million | $1.40 Million |
| Long-term Debt | — | — | — | — | $52.25K |
| Net Debt | $-145.42K | $-7.32 Million | $-11.08 Million | $-20.70 Million | $-13.73 Million |
| Total Stockholder Equity | $1.83 Million | $11.16 Million | $16.43 Million | $21.53 Million | $13.99 Million |
| Retained Earnings | $-166.38 Million | $-156.72 Million | $-150.21 Million | $-143.08 Million | $-136.05 Million |
Genetic Technologies Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Genetic Technologies Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-9.68 Million | $-9.72 Million | $-5.66 Million | $-6.30 Million | $-5.71 Million |
| Capital Expenditures | $32.97K | $17.55K | $96.79K | $642.00K | $38.10K |
| Free Cash Flow | $-9.71 Million | $-9.74 Million | $-5.76 Million | $-6.94 Million | $-5.75 Million |
| Investing Cash Flow | $114.90K | $-311.94K | $-3.49 Million | $-642.00K | $64.79K |
| Financing Cash Flow | $2.82 Million | $5.92 Million | $-279.06K | $13.94 Million | $18.36 Million |
| Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-Based Compensation | $124.18K | $253.45K | $437.51K | $714.58K | $-32.50K |
| Depreciation | $534.89K | $676.58K | $578.67K | $478.22K | $265.93K |
| Change in Cash | $-6.83 Million | $-3.88 Million | $21.37 Million | $6.69 Million | $12.08 Million |
Genetic Technologies Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Genetic Technologies Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 21, 2025 | — | — | — |
| Mar 19, 2024 | 0.00 | 0.00 | — |
| Oct 24, 2023 | 0.00 | 0.00 | — |
| Aug 29, 2023 | 0.00 | 0.00 | — |
| Apr 24, 2023 | 0.00 | 0.00 | — |
| Feb 23, 2023 | 0.00 | 0.00 | — |
| Oct 26, 2022 | 0.00 | 0.00 | — |
| Jun 30, 2021 | 0.00 | 0.00 | — |